Recent Company News

• 04:59 PM ET Oct 12, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:51 AM ET Oct 13, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 04:25 AM ET Oct 02, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (124 total)

• 09:43 AM ET Oct 01, 2026
  

  Transcript Intelligence: UCB Capital Markets Day

• 01:06 AM ET Sep 30, 2026
  

  UCB presents new data at EADV 2026 supporting earlier use of BIMZELX for treating hidradenitis suppurativa (€206.80, 0.00)

• 01:09 AM ET Sep 29, 2026
  

  UCB research at AANEM 2026 highlights advances in targeted treatments and patient-centered care for generalized Myasthenia Gravis (€212.50, 0.00)

• 02:55 AM ET Sep 09, 2026
  

  StreetAccount Summary - European pre-market trading update

• 01:09 AM ET Sep 09, 2026
  

  UCB's CIMZIA receives FDA Breakthrough Therapy designation for antiphospholipid syndrome (APS) in pregnant women (€206.90, 0.00)

• 09:11 AM ET Sep 01, 2026
  

  Oil & Gas, Health Care and Chemicals lead; Autos & Parts and Travel & Leisure lag: